Related Experiment Videos
Decreased platelet 3H-imipramine binding in Down's syndrome
1Psychopharmacology Unit, Clarke Institute of Psychiatry, Toronto, Ontario, Canada.
Psychiatry Research
|April 1, 1988
Summary
This study found lower serotonin transporter binding sites in individuals with Down syndrome compared to controls. This suggests potential serotonin metabolism defects in Down syndrome, measurable via platelet assays.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Down syndrome is associated with potential alterations in neurotransmitter systems.
- Serotonin plays a crucial role in brain function and mood regulation.
Purpose of the Study:
- To investigate serotonin transporter (SERT) levels in individuals with Down syndrome.
- To evaluate the utility of platelet 3H-imipramine binding as a biomarker for serotonin metabolism defects.
Main Methods:
- Utilized platelet 3H-imipramine binding assays to quantify serotonin transporter characteristics.
- Compared binding site density (Bmax) and affinity (Kd) in 12 subjects with Down syndrome against unrelated normal and parental controls.
Main Results:
- Significantly lower maximal number of binding sites (Bmax) for 3H-imipramine were observed in Down syndrome subjects.
- No significant differences in the affinity constant (Kd) were found between groups.
Conclusions:
- Platelet 3H-imipramine binding assays can detect reduced serotonin transporter levels in Down syndrome.
- This assay is a valuable tool for investigating serotonin metabolism abnormalities in human subjects.